Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
Amazon Explores AI Content Marketplace With Media Publishers 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Treasury Wine Estates Shares Surge After U.S. Dispute Settlement and Earnings Upgrade 
BURLINGTON, Mass., March 19, 2018 -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Michael Clayman, M.D., President and Chief Executive Officer, and Dan Deardorf, Senior Vice President, Commercial Operations, will participate in a fireside chat at Needham & Company's 17th Annual Healthcare Conference in New York City on Tuesday, March 27, 2018 at 10 a.m. ET. To access the live webcast and subsequent archived recording of the presentation, visit the Flexion website at http://ir.flexiontherapeutics.com.
About Flexion Therapeutics
Flexion Therapeutics (Nasdaq:FLXN) is a biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis, a type of degenerative arthritis. The company's core values are focus, ingenuity, tenacity, transparency and fun. Flexion was named one of The Boston Business Journal's 2017 Best Places to Work and one of the Top Places to Work in Massachusetts by The Boston Globe.
Contact:
Scott Young
Vice President, Corporate Communications and Investor Relations
Flexion Therapeutics, Inc.
T: 781-305-7194
[email protected]
